Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis

Cancer Research

Volumn 57, Issue 19, 1997, Pages 4267-4273

  Chiu, Chun Hung ^a   McEntee, Michael F ^a   Whelan, Jay ^a,b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; LEUKOTRIENE B4; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; COLON POLYPOSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG SCREENING; DRUG WITHDRAWAL; FATTY ACID SYNTHESIS; HETEROZYGOSITY; ICOSANOID METABOLISM; INTESTINE TUMOR; MALE; MOUSE; NONHUMAN; NONSENSE MUTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; TUMOR VOLUME;

ADENOMATOUS POLYPOSIS COLI; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; COLONIC NEOPLASMS; DINOPROSTONE; DISEASE SUSCEPTIBILITY; GENES, APC; HETEROZYGOTE; JEJUNAL NEOPLASMS; LEUKOTRIENE B4; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; PRODRUGS; PROSTAGLANDINS; REMISSION INDUCTION; SULINDAC;

EID: 0030758925     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Moser, A. R., Dove, W. F., Roth, K. A., and Gordon, J. I. The min (multiple intestinal neoplasia) mutation: its effects on gut epithelial cell differentiation and interaction with a modifier system. J. Cell Biol., 116: 1517-1526, 1992.
2. Levy, D. B., Smith, K. J., Beazer-Barclay, Y., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. Inactivation of both APC alleles in human and mouse tumors. Cancer Res., 54: 5953-5958, 1994.
3. Luongo, C., Moser, A. R., Gledhill, S., and Dove, W. F. Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res., 54: 5947-5952, 1994.
4. Kitagawa, T., and Lipkin, M. Molecular hiology of cancer, implications for prevention and therapy - Third Joint Meeting of the American Association for Cancer Research and the Japanese Cancer Association. Cancer Res., 55: 5472-5473, 1995.
5. Fodde, R., Edelmann, W., Yang, K., van Leeuwen, C., Carlson, C., Renault, B., Breukel, C., Alt, E., Lipkin, M., Khan, P. M., and Kucherlapati, R. A targeted chain-termination mutation in the mouse APC gene results in multiple intestinal tumors. Proc. Natl. Acad. Sci. USA, 91: 8969-8973, 1994.
6. DuBois, R. N. Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas. Gastroenterology, 108: 1310-1314, 1995.
7. Rosenberg, L., Palmer, J. R., Zauber, A. G., Warshauer, M. E., Stolley, P. D., and Shapiro, S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl. Cancer Inst., 83: 355-358, 1991.
8. Suh, O., Mettlin, C., and Petrelli, N. J. Aspirin use, cancer, and polyps of the large bowel. Clin. Investig., 72: 1171-1177, 1993.
9. Gann, P. H., Manson, J. E., Glynn, R. J., Buring, J. E., and Hennekens, C. H. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl. Cancer Inst., 85: 1220-1224, 1993.
10. Kune, G. A., Kune, S., and Watson, L. F. Colorectal cancer risk, chronic illnesses, operations, and medications: case-control results from the Melbourne colorectal cancer study. Cancer Res., 48: 4399-4404, 1988.
11. Peleg, I. I., Maibach, H. T., Brown, S. H., and Wicox, C. M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med., 154: 394-399, 1994.
12. Waddell, W. R., and Loughry, R. W. Sulindac for polyposis of the colon. J. Surg. Oncol., 24: 83-87, 1983.
13. Tonelli, F., Valanzano, R., and Dolara, P. Sulindac therapy of colorectal polyps in familial adenomatous polyposis. Dig. Dis., 12: 259-264, 1994.
14. Thun, M. J., Namboodiri, M. M., and Heath, C. W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.
15. Rao, C. V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V., and Reddy, B. S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55: 1464-1472, 1995.
16. Thompson, H. J., Briggs, S., Paranka, N. S., Piazza, G. A., Brendel, K., Gross, P. H., Sperl, G. J., Pamukcu, R., and Ahnen, D. J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J. Nail. Cancer Inst., 87: 1259-1260, 1995.
17. Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X. J., Ramonetti, J. T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., and Bertagnolli, M. M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56: 2556-2560, 1996.
18. Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., Staiano-Coico, L., Shiff, S. I., and Rigas, B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol., 52: 237-245, 1996.
19. Piazza, G. A., Rahm, A. L. K., Krutzsch, M., Sperl, G., Paranka, N. S., Gross, P. H., Brendel, K., Burt, R. W., Alberts, D. S., Pamukcu, R., and Ahnen, D. J. Antioneoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55: 3110-3116, 1995.
20. Piazza, G. A., Alberts, D. S., Hixson, L. I., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Richie, J., Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57: 2909-2915, 1997.
21. Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B. H., Li, H., Stoumen, A. L., Pamukcu, R., and Ahnen, D. J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res., 57: 2452-2459, 1997.
22. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. A. Treatment of colonic and rectal adenomas with sulindac in familial and adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
23. Shiff, S. J., Koutsos, M. I., Qiao, L., and Rigas, B. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle apoptosis. Exp. Cell Res., 222: 179-188, 1996.
24. Goldberg, Y., Nassif, I. I., Pittas, A., Tsai, L. L., Dynlacht, B. D., Rigas, B., and Shiff, S. J. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene, 12: 893-901, 1996.
25. Moorghen, M., Ince, P., Finney, K. J., Sunter, J. P., Appleton, D. R., and Watson, A. J. A protective effect of sulindac against chemically induced primary colonic tumours in mice. J. Pathol., 156: 341-347, 1988.
26. Whelan, J., Surette, M. E., Hardard'ottir, I., Lu, G-P., Golemboski, K. A., Larsen, E., and Kinsella, J. E. Dietary arachidonate enhances tissue arachidonate levels and eicosanoid production in Syrian hamsters. J. Nutr., 123: 2174-2185, 1993.
27. Markwell, M. A. K., Haas, S. M., Tolbert, N. E., and Bieber, L. L. Protein determinations in membrane and lipoprotein samples: manual and automated procedures. Methods Enzymol., 72: 296-303, 1981.
28. Thompson, H. J., Jiang, C., Lu, J., Mehta, R. G., Piazza, G. A., Paranka, N. S., Pamukcu, R., and Ahnen, D. J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res., 57: 267-271, 1997.
29. Li, B., Birdwell, C., and Whelan, J. Antithetic relationship of dietary arachidonic acid and eicosapentaenoic acid on eicosanoid production in vivo. J. Lipid Res., 35: 1869-1877, 1997.
30. Mann, N. J., Warrick, G. E., O'Dea, K., Knapp, H. R., and Sinclair, A. J. The effect of linoleic, arachidonic, and eicosapentaenoic acid supplementation on prostacyclin production in rats. Lipids, 29: 157-162, 1994.
31. Ferretti, A., Nelson, G. J., Schmidt, P. C., Kelley, D. S., Bartolinni, G., and Flanagan, V. P. Increased dietary arachidonic acid enhances the synthesis of vasoactive eicosanoids in humans. Lipids, 32: 435-439, 1997.
32. Moser, A. R., Luongo, C., Gould, K. A., McNeley, M. K., Shoemaker, A. R., and Dove, W. F. Apc Min: a mouse model for intestinal and mammary tumorigenesis. Eur. J. Cancer, 31A: 1061-1064, 1995.
33. Shoemaker, A. R., Moser, A. R., and Dove, W. F. N-Ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. Cancer Res., 55: 4479-4485, 1995.
34. Beazer-Barclay, Y., Levy, D. B., Moser, A. R., Dove, W. F., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis (Lond.), 17: 1757-1760, 1996.
35. Williams, C. S., Luongo, C., Radhika, A., Zhang, T., Lamps, L. W., Nanney, L. B., Beauchamp, R. D., and DuBois, R. N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 111: 1134-1140, 1996.
36. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Traskos, J. M., Evans, J. H., and Taketo, M. M. Suppression of intestinal polyposis in Apc-δ 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
37. Rigas, B., Goldman, I. S., and Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 722: 518-523, 1996.
38. Qiao, L., Kozoni, V., Tsioulias, G. J., Koutsos, M. I., Hanif, R., Shiff, S. J., and Rigas, B. Selected eicosanoids increase the proliferation in human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim. Biophys. Acta, 1258: 215-223, 1997.
39. Kargman, S. L., O'Neill, G. P., Vickers, P. J., Evans, I. F., Mancini, J. A., and Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55: 2556-2559, 1995.
40. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., and Hla, T. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res., 55: 3785-3789, 1995.
41. Duggan, D. E., Hare, L. E., Ditzler, C. A., Lei, B. W., and Kwan, K. C. The disposition of sulindac. Clin. Pharmacol. Ther., 21: 326-335, 1976.
42. Charalambous, D., and O'Brien, P. E. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J. Gastroenterol. Hepatol., 11: 307-310, 1996.